Dementia
Latest News
Advertisement
Latest Videos
Shorts
1:10
Who Needs a Biomarker Test for Dementia?
7 days ago
by
George Grossberg, MD
1:10
Narrowing the Gap in Dementia Diagnosis
8 days ago
by
George Grossberg, MD
1:50
Dementia & Benzodiazepines in Older Adults
2 months ago
by
Joseph F. Goldberg, MD(+1 more)
1:31
Treating Psychosis in Dementia With Zervimesine
6 months ago
by
Anthony Caggiano, MD, PhD
1:46
New Monoclonal Antibodies: Remternetug for Alzheimer Disease
6 months ago
by
Matan Dabora, MD, MBA(+1 more)
CME Content
Advertisement
More News
New donanemab dosing cuts ARIA-E risk, speeds MRI monitoring, and shows durable 3-year benefits with lasting biomarker gains in early Alzheimer’s.
Plasma P-tau217 blood tests match amyloid PET for early Alzheimer pathology, offering scalable, noninvasive detection and forecasting cognitive decline risk years ahead.
New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.
Data suggest PBFT02 therapy boosts progranulin and slows neurodegeneration markers in early FTD.
Shared pathophysiology between Alzheimer disease and autism may expand diagnosis and treatment opportunities.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Neflamapimod for Dementia With Lewy Bodies Misses End Point, Subgroup Signal Emerges
5